Sionna Therapeutics reports Q4 EPS ($3.38) vs. ($3.93) last year
Sionna including strong clinical execution across multiple programs. Encouraging interim Phase 1 data for SION-719 and SION-451, our highly potent nucleotide-binding domain 1 stabilizers, showed that ...
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th ...
Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...
New Data On Investigational Therapy For Thymidine Kinase 2 Deficiency Presented At Muscular ...
Clinical data highlight survival benefits and improvement in functional motor outcomes associated with treatment with doxecitine (dC) and ...
Mapping maternal lineages of fine aroma cocoa through chloroplast DNA
Toribio Rodríguez de Mendoza National University researchers conducted a genomic analysis of fine aroma cocoa from northern ...
eLife5 天
Thrifty wide-context models of B cell receptor somatic hypermutation
They also show that models learned from nonsynonymous mutations and from out-of-frame sequences are different, prompting new questions about germinal center function. Strengths of the study include an ...
Physician's Weekly5 天
Polygenic Score Shows Promise for Evaluating AUD Risk
The polygenic score calculated using concordant single-nucleotide variants may be a method to evaluate risk for alcohol use ...
Taiwan News6 天
Scientists Solve One of Genomics’ Biggest Challenges by Using HiFi Sequencing to ...
PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for ...